Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K; Australasian Leukemia and Lymphoma Group. Spencer A, et al. Among authors: prosser i. Bone Marrow Transplant. 2005 May;35(10):971-7. doi: 10.1038/sj.bmt.1704946. Bone Marrow Transplant. 2005. PMID: 15778725 Clinical Trial.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui CH, Prosser I, Lewis ID, Bradstock K, Seymour JF; Australasian Leukaemia and Lymphoma Group. Hapgood G, et al. Among authors: prosser i. Leuk Lymphoma. 2019 Apr;60(4):904-911. doi: 10.1080/10428194.2018.1516873. Epub 2018 Dec 14. Leuk Lymphoma. 2019. PMID: 30547695 Clinical Trial.
Novel therapeutic option for orbital atypical lymphoid hyperplasia.
Talaulikar D, Tridgell D, Leong D, Dahlstrom JE, Cherian M, Prosser I, Sunderland K. Talaulikar D, et al. Among authors: prosser i. Clin Exp Ophthalmol. 2010 Dec;38(9):892-4. doi: 10.1111/j.1442-9071.2010.02378.x. Clin Exp Ophthalmol. 2010. PMID: 20662847
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF. Kenealy M, et al. Among authors: prosser i. Leuk Lymphoma. 2017 Feb;58(2):298-307. doi: 10.1080/10428194.2016.1190971. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27268068 Clinical Trial.
Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia.
Bradstock KF, Morley A, Byth K, Szer J, Prosser I, Cannell P, Irving I, Seymour JF. Bradstock KF, et al. Among authors: prosser i. Contemp Clin Trials Commun. 2016 Jun 22;4:9-13. doi: 10.1016/j.conctc.2016.06.004. eCollection 2016 Dec 15. Contemp Clin Trials Commun. 2016. PMID: 29736466 Free PMC article.
72 results